Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RAPP Stock 12 Month Forecast
Average Price Target
$33.67
▲(134.47% Upside)
| Highest Price Target$42.00 | Average Price Target$33.67 | Lowest Price Target$28.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$42
Buy
192.48%
Upside
Reiterated
08/28/25
H.C. Wainwright
$31
Buy
115.88%
Upside
Reiterated
08/11/25
Analysts Conflicted on These NA Names: Core Scientific Inc (NASDAQ: CORZ) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)Valuation and Risks. Our Buy rating and $31 price target for Rapport are based on 6x our 2035 risk-adjusted revenue estimate of $301M for Rapport discounted back to the present. Our 6x multiple is consistent with EV/sales multiples we see across other innovative CNS companies in our coverage and also consistent with valuation multiples we see in recent and historical M&A transactions. We adjust each product for the probability of success (PoS) with RAP-219 oral formulation at 65% in refractory FOS given its compelling drug profile and Phase 1 data, and 25% in bipolar mania as Phase 2 study has been initiated.
TD Cowen
―
Buy
―
Reiterated
08/07/25
We note that the effect on clinical seizures has been a key investor question. Based on KOL feedback and medical literature if the LE bar is hit, this should correspond with the secondary endpoint of ≥40% responders with a ≥50% clinical seizure reduction being achieved. We caution that the trial is open-label and not powered toward the CS endpoint, thus while numbers of this magnitude would be very encouraging, stats should not be the expectation. For more information see our detailed data preview here (p.190).
Citizens JMP
$28
Buy
94.99%
Upside
Reiterated
07/16/25
Stifel Nicolaus
$35
Buy
143.73%
Upside
Reiterated
06/03/25
Jefferies
$35
Buy
143.73%
Upside
Assigned
12/07/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$42
Buy
192.48%
Upside
Reiterated
08/28/25
H.C. Wainwright
$31
Buy
115.88%
Upside
Reiterated
08/11/25
Analysts Conflicted on These NA Names: Core Scientific Inc (NASDAQ: CORZ) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)Valuation and Risks. Our Buy rating and $31 price target for Rapport are based on 6x our 2035 risk-adjusted revenue estimate of $301M for Rapport discounted back to the present. Our 6x multiple is consistent with EV/sales multiples we see across other innovative CNS companies in our coverage and also consistent with valuation multiples we see in recent and historical M&A transactions. We adjust each product for the probability of success (PoS) with RAP-219 oral formulation at 65% in refractory FOS given its compelling drug profile and Phase 1 data, and 25% in bipolar mania as Phase 2 study has been initiated.
TD Cowen
―
Buy
―
Reiterated
08/07/25
We note that the effect on clinical seizures has been a key investor question. Based on KOL feedback and medical literature if the LE bar is hit, this should correspond with the secondary endpoint of ≥40% responders with a ≥50% clinical seizure reduction being achieved. We caution that the trial is open-label and not powered toward the CS endpoint, thus while numbers of this magnitude would be very encouraging, stats should not be the expectation. For more information see our detailed data preview here (p.190).
Citizens JMP
$28
Buy
94.99%
Upside
Reiterated
07/16/25
Stifel Nicolaus
$35
Buy
143.73%
Upside
Reiterated
06/03/25
Jefferies
$35
Buy
143.73%
Upside
Assigned
12/07/24
Best Analysts Covering Rapport Therapeutics, Inc.
1 Month
xxx
Success Rate
5/8 ratings generated profit
Average Return
+1.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +1.44% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+6.02%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.02% per trade.
1 Year
Success Rate
6/8 ratings generated profit
Average Return
+20.35%
reiterated a buy rating 10 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +20.35% per trade.
2 Years
xxx
Success Rate
6/8 ratings generated profit
Average Return
+20.35%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +20.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RAPP Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
5
7
6
11
Buy
1
2
3
3
3
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
10
9
14
Each month's total comprises the sum of three months' worth of ratings.
RAPP Financial Forecast
RAPP Stock Forecast FAQ
What is RAPP’s average 12-month price target, according to analysts?
Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is 33.67.
What is RAPP’s upside potential, based on the analysts’ average price target?
Rapport Therapeutics, Inc. has 134.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAPP a Buy, Sell or Hold?
Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rapport Therapeutics, Inc.’s price target?
The average price target for Rapport Therapeutics, Inc. is 33.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $42.00 ,the lowest forecast is $28.00. The average price target represents 134.47% Increase from the current price of $14.36.
The highest analyst price target is $42.00 ,the lowest forecast is $28.00. The average price target represents 134.47% Increase from the current price of $14.36.
What do analysts say about Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of RAPP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.